Sign in to view content

Intermittent to Continuous Therapy for Diabetic Macular Edema leads to Reduction in Treatment Frequency and Reduced Retinal Thickness Fluctuations

Seenu M. Hariprasad, MD

Video
Published 2019

Related

The Translation of CST to Visual Function: Persistent DME and QOL Measures With FAc Implants in the FAME Study
Michael A. Singer, MD
Annual Meeting Talks
2018
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more